GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Il Dong Pharmaceutical Co 249420.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

12,250

0.00%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Il Dong Pharmaceutical Co

Its shares trade on KRX under the ticker 249420.KS. It has been listed since 31 August 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩566.93bn and net income of ₩27.66bn. At that date it held total assets of ₩573.03bn and shareholders' equity of ₩246.42bn.

Ildong Pharmaceutical Co., Ltd. engages in the manufacture and sale of medicines, ingredients for medicines, health supplements and special nutritional products. The company is headquartered in Seoul, Seoul. The company went IPO on 2016-08-31.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
31 Aug 2016
Website
ildong.com ↗

Leadership

Pay as last reported

  • Mr. Jin Sik SeoCo-President, Chief Operating Officer, Director
  • Mr. Seong Gu ChoiCo-President, Director
  • Mr. Wung Seop YoonChief Executive Officer, Vice Chairman₩721.7m
  • Mr. Gyu Seong KangChief Financial Officer, Director
  • Mr. Deok Won KangVice President
  • Mr. Jae Jun LeeVice President
  • Mr. Seok Je ChoManaging Director
  • Mr. Seung Su KimManaging Director
  • Mr. Wan Su KimManaging Director
  • Mr. Won Rang KimManaging Director
  • Ms. Sin Yeong LeeManaging Director
  • Mr. Jeong Seop 'Internal Auditor

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seoul, South Korea
  • Engages in manufacturing and selling medicines and health supplements
  • Listed on the stock market with IPO date of 2016-08-31

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market position provided
  • No information on competitive advantages or unique products

Opportunities

  • Potential growth in the pharmaceutical sector in South Korea
  • Expansion into health supplements and special nutritional products
  • Opportunities from the company's IPO listing for capital raising

Threats

  • No specific threats mentioned in the provided information
  • No details on market competition or regulatory challenges
  • No information on economic or industry risks

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.